Residency · Residency · Physical Medicine Rehabilitation

Post-Traumatic Agitation Management in TBI

Overview

Definition

Post-traumatic agitation (PTA-related agitation) is a subtype of delirium occurring during the period of post-traumatic amnesia following TBI. Characterized by excess of behavior including aggression, disinhibition, akathisia, emotional lability, and restlessness. Occurs in up to 70% of patients with moderate-to-severe TBI during acute rehabilitation. Typically emerges as patients transition from coma/DOC to confusional state (Rancho Los Amigos Level IV). Self-limited in most cases but can persist for weeks to months.

Pathophysiology

Diffuse axonal injury affecting frontal-subcortical circuits (inhibitory control). Disruption of neurotransmitter systems: dopaminergic, noradrenergic, serotonergic, cholinergic, GABAergic. Impaired arousal regulation from brainstem reticular activating system injury. Temporal and frontal lobe contusions are particularly associated with agitation. Neuroinflammatory cascade contributes to behavioral dysregulation.

Assessment

Agitated Behavior Scale (ABS)

Most widely used standardized measure of agitation after TBI. 14 items rated 1-4 (1 = absent, 4 = extreme). Total score range: 14-56. Score >21 indicates clinically significant agitation.

Subcategories: aggression, disinhibition, lability. Should be scored serially (every shift or daily) to track trajectory and treatment response.

Differential Diagnosis of Agitation

Must exclude treatable medical causes before attributing agitation to TBI itself: Pain: fractures, heterotopic ossification, headache, constipation, bladder distention. Infection: UTI, pneumonia, wound infection, meningitis/ventriculitis. Hydrocephalus: new or worsening.

Seizures: subclinical or post-ictal state. Medication effects: paradoxical reactions, withdrawal (alcohol, benzodiazepines, opioids). Sleep disturbance: disrupted circadian rhythm. Metabolic: electrolyte abnormalities, hepatic/renal dysfunction, thyroid dysfunction.

Environmental: overstimulation, unfamiliar setting, restraints. Workup: vital signs, pain assessment, urinalysis, CBC, CMP, medication review, CT head (if new or worsening), consider EEG.

<image>Flowchart for evaluation of post-traumatic agitation showing initial assessment with Agitated Behavior Scale scoring, differential diagnosis workup to exclude pain, infection, hydrocephalus, seizures, medication effects, and metabolic causes, followed by environmental and behavioral interventions before pharmacologic management</image>

Environmental and Behavioral Management

Environmental Modifications (First-Line)

Reduce environmental stimulation: single room, minimize noise, reduce lighting, limit visitors. Familiar objects and photos from home. Consistent daily routine and staff assignment. Minimize physical restraints (restraints often worsen agitation and increase injury risk).

Bed in lowest position with padded side rails or floor mats. Remove IVs, catheters, and lines when medically feasible. 1:1 sitter or nursing supervision for safety.

Behavioral Strategies

Calm, consistent, and reassuring communication. Simple one-step commands; avoid arguing or reasoning with the patient. Redirect rather than confront. Allow safe wandering in a contained, supervised environment.

Engage in purposeful activity when possible (even simple tasks). Structured therapy sessions with frequent breaks. Minimize frustration by matching task demands to cognitive level. Family education: normalize the behavior, teach de-escalation techniques.

Restraint Minimization

Physical restraints should be a last resort and used for the shortest duration possible. Restraints increase agitation, injury risk, and can prolong confusion. Mittens preferred over wrist restraints if hand protection needed. Craig bed or enclosed bed systems may be safer alternatives. Document medical necessity and reassess frequently.

Pharmacologic Management

General Principles

Pharmacotherapy is adjunctive to environmental and behavioral management. "Start low, go slow" dosing approach. Avoid medications that impair neuroplasticity and cognitive recovery. Target specific symptom domains (aggression, restlessness, sleep-wake dysregulation).

Reassess regularly and taper medications as agitation resolves. The goal is to facilitate safe participation in rehabilitation, not sedation.

First-Line Agents

Amantadine

NMDA receptor antagonist and dopamine agonist. Evidence: randomized controlled trial (Giacino et al., 2012) demonstrated accelerated recovery. Also reduces agitation (Hammond et al.). Dose: 100 mg BID (morning and noon; avoid evening dosing due to insomnia).

May increase to 200 mg BID. Side effects: insomnia, hallucinations, seizure (rare). Preferred agent for agitation with hypoarousal or poor initiation.

Beta-Blockers (Propranolol, Pindolol)

Propranolol 20-60 mg TID (most studied beta-blocker for TBI agitation). Mechanism: reduces noradrenergic hyperactivity. Effective for aggressive/violent behavior specifically. Monitor for bradycardia, hypotension, bronchospasm.

Contraindicated in asthma, severe bradycardia, decompensated heart failure. Evidence: several positive small RCTs and case series.

Second-Line Agents

Antiepileptic Mood Stabilizers

Valproic acid: 250-500 mg BID, titrate to therapeutic level (50-100 mcg/mL); useful for aggression and lability; monitor LFTs, platelets, ammonia. Carbamazepine: alternative; monitor CBC and sodium. Avoid phenytoin if possible (impairs cognitive recovery).

SSRIs

Sertraline 25-100 mg daily or citalopram 10-20 mg daily. Useful when emotional lability or depression coexists with agitation. Takes 2-4 weeks for full effect; not effective for acute agitation. Favorable side effect profile in TBI population.

Buspirone

5HT1A partial agonist. 5-15 mg TID; takes 1-2 weeks for effect. May reduce anxiety and aggression. No sedation or cognitive impairment; no dependence risk.

Agents to Use with Caution

Atypical Antipsychotics

Quetiapine 25-100 mg at bedtime for nocturnal agitation. Olanzapine, risperidone: may be needed for severe agitation with psychotic features. Concerns: dopamine blockade may impair neuroplasticity and motor recovery. Use the lowest effective dose for the shortest duration. Quetiapine is generally preferred due to lower D2 receptor affinity.

Agents to AVOID

Typical Antipsychotics (Haloperidol)

Strong D2 blockade impairs dopaminergic recovery pathways. Animal studies show worse outcomes after TBI with haloperidol exposure. Increased risk of extrapyramidal symptoms, neuroleptic malignant syndrome. Should be avoided unless acute psychiatric emergency and no alternatives.

Benzodiazepines

Impair cognitive recovery, memory consolidation, and neuroplasticity. Paradoxical agitation is common in TBI population. Increase fall risk and sedation. May be necessary for acute alcohol or benzodiazepine withdrawal management. Avoid for routine agitation management.

<image>Table-style illustration comparing pharmacologic agents for post-traumatic agitation organized by recommendation tier, showing first-line agents (amantadine, propranolol), second-line agents (valproic acid, SSRIs, buspirone), agents to use cautiously (atypical antipsychotics), and agents to avoid (haloperidol, benzodiazepines), with key mechanisms and side effect profiles</image>

Special Considerations

Paroxysmal Sympathetic Hyperactivity (PSH)

Previously termed sympathetic storming, dysautonomia, or diencephalic seizures. Episodic tachycardia, hypertension, tachypnea, diaphoresis, posturing, and fever. Can be triggered by pain, stimulation, or occur spontaneously. Diagnosis supported by the PSH-Assessment Measure (PSH-AM).

Distinguished from agitation by the prominent autonomic features and lower level of consciousness. Treatment: remove triggers, morphine or fentanyl for episodes, propranolol, clonidine, bromocriptine, gabapentin, dantrolene, baclofen.

Sleep-Wake Cycle Dysregulation

Disrupted circadian rhythm is almost universal after moderate-severe TBI. Melatonin 3-5 mg at bedtime may help regulate sleep-wake cycle. Trazodone 25-100 mg at bedtime for insomnia. Maintain consistent wake-sleep schedule with daytime light exposure. Avoid sedating medications during the day.

Post-Traumatic Seizures

Risk of early seizures (<7 days): 10-15% after severe TBI. Prophylaxis with levetiracetam (preferred) for the first 7 days. No evidence supporting prophylaxis beyond 7 days for prevention of late seizures. Seizures can present as agitation, staring, or behavioral change. Consider continuous EEG monitoring if agitation is unexplained or episodic.

Monitoring and Documentation

Serial Assessment

ABS scores at least daily (preferably every shift). Track specific behaviors: physical aggression, verbal aggression, self-injury, elopement risk. Document medication changes and behavioral interventions with correlation to ABS scores. Safety events: falls, staff injuries, use of restraints.

Recovery Trajectory

Most post-traumatic agitation resolves within 2-4 weeks as PTA clears. Persistent agitation beyond PTA resolution warrants further evaluation (frontal lobe injury, pre-morbid psychiatric conditions, substance use history). Gradual medication taper as agitation improves; avoid abrupt discontinuation.

Clinical Pearls

Always exclude treatable medical causes (pain, infection, hydrocephalus, seizures) before attributing agitation to the TBI itself. Environmental and behavioral interventions are always the first step and remain the foundation of management. Amantadine and propranolol are the best-supported first-line pharmacologic agents for TBI agitation. Avoid haloperidol and benzodiazepines whenever possible; both impair neuroplasticity and cognitive recovery.

Physical restraints often worsen agitation; minimize their use and explore alternatives. Agitation during PTA is a phase of recovery, not a behavioral problem; educate families accordingly. Distinguish paroxysmal sympathetic hyperactivity from agitation; they have different mechanisms and treatments. Always plan for medication tapering once agitation resolves; many post-TBI agitation medications are not needed long-term.

References

• Giacino JT, et al. Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. N Engl J Med. 2012;366(9):819-826.
• Hammond FM, et al. Effectiveness of Amantadine Hydrochloride in the Reduction of Chronic Traumatic Brain Injury Irritability and Aggression. J Head Trauma Rehabil. 2014;29(5):391-399.
• Fleminger S, et al. Pharmacological Management for Agitation and Aggression in People with Acquired Brain Injury. Cochrane Database Syst Rev. 2006.
• Baguley IJ, et al. Paroxysmal Sympathetic Hyperactivity After Acquired Brain Injury: Consensus on Conceptual Definition, Nomenclature, and Diagnostic Criteria. J Neurotrauma. 2014;31(17):1515-1520.
• Plantier D, Bhatt T. Pharmacological Management of Agitation During and After Traumatic Brain Injury. Ann Phys Rehabil Med. 2016;59(suppl):e100.

Read this lecture as Markdown